


## Trends in median annual price for disease-modifying therapies for multiple sclerosis by category; 1997 to 2020



| Drug                      | 5 Year Change* | 1 Year Change** | Annual Cost 2020 |
|---------------------------|----------------|-----------------|------------------|
| <b>Interferons</b>        |                |                 |                  |
| Betaseron                 | 48.9%          | 4.6%            | \$103,302        |
| Avonex                    | 48.0%          | 2.0%            | \$91,835         |
| Rebif                     | 46.7%          | 4.8%            | \$103,647        |
| Extavia                   | 39.0%          | 0.0%            | \$81,079         |
| Plegridy                  | 48.0%          | 2.0%            | \$91,835         |
| <b>Glatiramer Acetate</b> |                |                 |                  |
| Copaxone 20               | 16.4%          | 0.0%            | \$86,554         |
| Copaxone 40               | 16.5%          | 0.0%            | \$75,816         |
| Glatopa 20                |                | -71.1%          | \$18,250         |
| Glatopa 40                |                | -70.2%          | \$19,500         |
| Glat Acet 20              |                | 0.0%            | \$23,725         |
| Glat Acet 40              |                | 0.0%            | \$25,350         |
| <b>Oral DMTs</b>          |                |                 |                  |
| Gilenya                   | 58.2%          | 5.5%            | \$105,390        |
| Aubagio                   | 40.9%          | 5.0%            | \$93,296         |
| Tecfidera                 | 59.9%          | 6.0%            | \$100,690        |
| Mayzent                   |                |                 | \$93,367         |
| Mavenclad                 |                |                 | \$107,460        |
| Vumerity                  |                |                 | \$88,000         |
| <b>Infusions</b>          |                |                 |                  |
| Tysabri                   | 38.1%          | 7.1%            | \$89,074         |
| Lemtrada                  | 22.0%          | 5.2%            | \$80,320         |
| Ocrevus                   |                | 0.0%            | \$65,000         |

Notes:  
 Annual price estimated from wholesale acquisition costs (First Databank)  
 Dashed line is projected annual price of Betaseron assuming only inflationary increases in price (medical care)  
 \*The annual price for Lemtrada is based on four 12 mg vials (Package insert dosing: 12 mg/day (5 vials) for five consecutive days in first year; 12 mg/day (3 vials) for three days in year 2)  
 \*\*2015 to 2020 (Feb); \*\*2019 to 2020 (Feb)  
 Updated 2.20.2020

Hartung, DM- PharmD, MPH; Oregon State University/Oregon Health and Science University


## The National MS Society

modifying therapies (DMTs). 77% of respondents reported taking one of the following six medications:

| DMT              | Annual Cost   | 5 Year Change | DMT            | Annual Cost | 5 Year Change |
|------------------|---------------|---------------|----------------|-------------|---------------|
| <b>Ocrevus</b>   | \$65,000      | n/a           | <b>Tysabri</b> | \$89,074    | 38.1%         |
| <b>Tecfidera</b> | \$100,690     | 59.9%         | <b>Gilenya</b> | \$105,390   | 58.2%         |
| <b>Copaxone</b>  | \$75K - \$86K | 16.5%         | <b>Aubagio</b> | \$93,296    | 40.9%         |

- Only 11% of those **with MS** said they could easily afford their DMT without financial assistance
- **More than half** are very concerned about how they will afford their medication in the future
- **85%** think the federal government should do more to control the high cost of MS medications

## How have you altered use of an MS DMT?



With the rising cost of DMTs, **40% of those living with MS** are not able to stick to their treatment plan as prescribed by their provider. And **more than 1 in 10** of those surveyed stopped use of their DMT entirely, which opens the door to progression of MS.